NewsMV
Milwaukee-based law firm Ademi LLP has opened an investigation into Theravance Biopharma, Inc.
(NASDAQ: TBPH) over its recently announced transaction with Zymeworks, examining whether the deal adequately compensates public shareholders.
The inquiry centers on potential breaches of fiduciary duty and other violations of law by Theravance's board in connection with the proposed combination.
What Ademi Is Examining The core question Ademi LLP is pursuing is whether Theravance Biopharma's directors fulfilled their legal obligations to ordinary shareholders when they agreed to terms with Zymeworks.
Keep reading